ReviewDiabetology & metabolic syndrome2026
Effects of time-restricted eating on people with type 2 diabetes: a systematic review and meta-analysis.
Review in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLong-term dietary adherence remains a challenge in the management of type 2 diabetes (T2DM). Time-restricted eating (TRE), a dietary strategy that confines daily food intake to a specific time window, has emerged as a potential intervention. However, its efficacy in individuals with T2DM remains unclear. This review aimed to comprehensively evaluate the effects of TRE in this population.
methodsA systematic search of PubMed, Embase, Scopus, Web of Science, and the Cochrane Library was conducted from inception to April 7, 2025, for interventional studies on TRE in adults with T2DM. Outcomes encompassed glucose metabolism, body weight, lipid profiles, dietary intake, sleep, and other physiological indicators. Data were pooled using random-effects model.
resultsThe review included 12 studies involving 344 participants. TRE significantly reduced HbA1c (MD: -0.32%, 95% CI: -0.47 to -0.18) and fasting blood glucose (MD: -0.44 mmol/L, 95% CI: -0.68 to -0.19). Continuous glucose monitoring (CGM) data corroborated these improvements, showing an increased time in range (MD: 8.92%, 95% CI: 3.94 to 13.91) and a decreased time above range (MD: -11.42%, 95% CI: -15.53 to -7.30). These glycemic improvements were accompanied by a reduction in the medication effect score (MD: -0.15, 95% CI: -0.27 to -0.03). Furthermore, TRE led to improvements in weight-related indicators (body weight, BMI, and waist circumference) and in cardiovascular metabolic parameters, such as reductions in triglycerides and blood pressure (all p<0.05). In contrast, TRE did not significantly affect cholesterol levels or total sleep duration (all p ≥ 0.05), but was associated with prolonged sleep latency (SMD: 0.74, 95% CI:0.22 to 1.26).
conclusionTRE represents a promising dietary intervention for individuals with T2DM, associated with improved glycemic control, weight management, and certain cardiovascular metabolic indices, alongside a potential reduction in medication requirements. However, it did not affect cholesterol or total sleep time and may prolong sleep latency. Further high-quality research is warranted to confirm these findings and optimize its clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.